JP5946459B2 - 腫瘍形成（ｎｅｏｐｌａｓｉａ）を治療するための組成物および方法 - Google Patents

腫瘍形成（ｎｅｏｐｌａｓｉａ）を治療するための組成物および方法 Download PDF

Info

Publication number
JP5946459B2
JP5946459B2 JP2013529675A JP2013529675A JP5946459B2 JP 5946459 B2 JP5946459 B2 JP 5946459B2 JP 2013529675 A JP2013529675 A JP 2013529675A JP 2013529675 A JP2013529675 A JP 2013529675A JP 5946459 B2 JP5946459 B2 JP 5946459B2
Authority
JP
Japan
Prior art keywords
chimeric antibody
antibody
cell
chimeric
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013529675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541944A (ja
JP2013541944A5 (cg-RX-API-DMAC10.html
Inventor
シデラ カテリーナ
シデラ カテリーナ
ママラキ アヴギ
ママラキ アヴギ
パトサヴーディ エヴァンゲリア
パトサヴーディ エヴァンゲリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zestagen SA
Original Assignee
Zestagen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zestagen SA filed Critical Zestagen SA
Publication of JP2013541944A publication Critical patent/JP2013541944A/ja
Publication of JP2013541944A5 publication Critical patent/JP2013541944A5/ja
Application granted granted Critical
Publication of JP5946459B2 publication Critical patent/JP5946459B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013529675A 2010-09-27 2011-09-27 腫瘍形成（ｎｅｏｐｌａｓｉａ）を治療するための組成物および方法 Expired - Fee Related JP5946459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38676410P 2010-09-27 2010-09-27
US61/386,764 2010-09-27
PCT/EP2011/066791 WO2012041863A1 (en) 2010-09-27 2011-09-27 Compositions and methods for treating neoplasia

Publications (3)

Publication Number Publication Date
JP2013541944A JP2013541944A (ja) 2013-11-21
JP2013541944A5 JP2013541944A5 (cg-RX-API-DMAC10.html) 2014-11-13
JP5946459B2 true JP5946459B2 (ja) 2016-07-06

Family

ID=44675608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529675A Expired - Fee Related JP5946459B2 (ja) 2010-09-27 2011-09-27 腫瘍形成（ｎｅｏｐｌａｓｉａ）を治療するための組成物および方法

Country Status (12)

Country Link
US (2) US9115192B2 (cg-RX-API-DMAC10.html)
EP (1) EP2621947A1 (cg-RX-API-DMAC10.html)
JP (1) JP5946459B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140016240A (cg-RX-API-DMAC10.html)
CN (1) CN103459420B (cg-RX-API-DMAC10.html)
AU (1) AU2011310664B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013007327A2 (cg-RX-API-DMAC10.html)
CA (1) CA2812644A1 (cg-RX-API-DMAC10.html)
IL (1) IL225483A0 (cg-RX-API-DMAC10.html)
MX (1) MX2013003561A (cg-RX-API-DMAC10.html)
SG (1) SG189095A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012041863A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US10877024B2 (en) * 2015-05-12 2020-12-29 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도

Also Published As

Publication number Publication date
BR112013007327A2 (pt) 2017-07-04
US20160075771A1 (en) 2016-03-17
US20130280244A1 (en) 2013-10-24
KR20140016240A (ko) 2014-02-07
SG189095A1 (en) 2013-05-31
IL225483A0 (en) 2013-06-27
MX2013003561A (es) 2013-09-02
CN103459420B (zh) 2016-09-28
CA2812644A1 (en) 2012-04-05
WO2012041863A1 (en) 2012-04-05
AU2011310664A1 (en) 2013-05-09
AU2011310664B2 (en) 2016-02-18
JP2013541944A (ja) 2013-11-21
US9115192B2 (en) 2015-08-25
CN103459420A (zh) 2013-12-18
EP2621947A1 (en) 2013-08-07
US9328161B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
AU2011310664B2 (en) Compositions and methods for treating neoplasia
JP5586454B2 (ja) ヒトｄｌｌ４に対する中和モノクローナル抗体
KR101960004B1 (ko) Cldn6 생체내 표적-지향된 항체를 이용하는 암 치료법
US10208125B2 (en) Anti-mucin 1 binding agents and uses thereof
CN101820910B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
JP2020526478A (ja) 抗ＣＤ４７ｘ抗メソテリン抗体およびそれを使用する方法
AU2016203575A1 (en) Novel anti-DR5 antibody
CA2906688A1 (en) Cancer treatment using antibodies that bind cell surface grp78
JP5328155B2 (ja) Ａｄａｍ−９モジュレータ
KR102701695B1 (ko) 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
CN107708731A (zh) 治疗癌症的组合疗法
CN106659778A (zh) 用Notch1抗体治疗癌症的方法
US10064937B2 (en) Treatment of dermal fibrosis
JP5896568B2 (ja) 動脈硬化又は動脈硬化性疾患の治療剤、及び動脈硬化又は動脈硬化性疾患の診断薬
WO2021202592A2 (en) Monoclonal antibodies for intracellular delivery of payloads
JP2013013327A (ja) Ｍａｎｓｃ１蛋白質に結合し、抗癌活性を有する抗体
HK40033721A (en) Anti-mucin 1 binding agents and uses thereof
HK1226813A1 (en) Anti-mucin 1 binding agents and uses thereof
HK1226813B (en) Anti-mucin 1 binding agents and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160531

R150 Certificate of patent or registration of utility model

Ref document number: 5946459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees